MARA HOE ESTRIBOU DESIGN 269 8th Street #2L Brooklyn, NY 11215 917 699 4514 mara @ mheDesign.com CLIENTS INCLUDE: AGFA AIG TECHNOLOGIES AMERICAN EXPRESS AMERICAN MUSEUM OF NATURAL HISTORY AXA BONDBOOK CATERPILLAR CHUBB CITY OF NEW YORK CLIFFORD CHANCE FISH & NEAVE FWA GE GUARDIAN GUGGENHEIM MUSEUM / LEARNING THROUGH ART HERTZ JETBLUE JOHN HANCOCK LEHMAN BROTHERS LORD, ABBETT & CO. LUCENT TECHNOLOGIES MANULIFE WOOD LOGAN MASTERCARD MERRILL LYNCH MILBANK NORTHFORK BANCORP NOVARTIS NYSE ORTHO-MCNEIL PIRELLI PRUDENTIAL SECURITIES SAMSUNG SANOFI AVENTIS SCO FAMILY OF SERVICES SERONO SPACEHAB U.S. TRUST VERIZON WHITNEY MUSEUM OF AMERICAN ART W.P. CAREY WYETH XEROX
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
MARA HOE ESTRIBOU DESIGN
269 8th Street #2L Brooklyn, NY 11215
917 699 [email protected]
CLIENTS INCLUDE:AGFAAIG TECHNOLOGIESAMERICAN EXPRESSAMERICAN MUSEUM OF NATURAL HISTORYAXABONDBOOKCATERPILLARCHUBBCITY OF NEW YORKCLIFFORD CHANCEFISH & NEAVEFWAGEGUARDIANGUGGENHEIM MUSEUM / LEARNING THROUGH ARTHERTZJETBLUEJOHN HANCOCKLEHMAN BROTHERSLORD, ABBETT & CO.LUCENT TECHNOLOGIESMANULIFE WOOD LOGANMASTERCARDMERRILL LYNCHMILBANKNORTHFORK BANCORPNOVARTISNYSEORTHO-MCNEILPIRELLI PRUDENTIAL SECURITIESSAMSUNGSANOFI AVENTISSCO FAMILY OF SERVICESSERONOSPACEHABU.S. TRUSTVERIZONWHITNEY MUSEUM OF AMERICAN ARTW.P. CAREYWYETHXEROX
MARA HOE ESTRIBOU LUCENT TECHNOLOGIES / ANNUAL REPORT
MARA HOE ESTRIBOU LUCENT TECHNOLOGIES / ENVIRONMENT, HEALTH AND SAFETY REPORT
MARA HOE ESTRIBOU JOHN HANCOCK / VARIABLE ANNUITIES MARKETING LITERATURE
MARA HOE ESTRIBOU MASTERCARD WORLDWIDE / B-TO-B TOOLKIT / L ITERATURE SYSTEM, FLASH DEMO
MARA HOE ESTRIBOU MASTERCARD WORLDWIDE / B-TO-B TOOLKIT / L ITERATURE SYSTEM, FLASH DEMO
MARA HOE ESTRIBOU MILBANK / RECRUITING BROCHURE
MARA HOE ESTRIBOU BONDBOOK / IDENTITY
SCOPE OF WORK:
LOGO DESIGN AND BRAND IDENTIFICATION GUIDELINES
BRAND MESSAGING
MARKETING LITERATURE AND SELL SHEETS
CORPORATE WEB SITE
TRADING PLATFORM (FRONT-END AND BACK END INTERFACES)
NATIONAL ADVERTISING
NEWSLETTERS AND PRESS RELEASES
STATIONERY SYSTEM(BOTH PRINTED AND ELECTRONIC)
EXTENSIVE FORMS SYSTEM(BOTH PRINTED AND ELECTRONIC)
POWERPOINT TEMPLATES AND PRESENTATION MATERIALS
TRADE SHOW GRAPHICS
PROMOTIONAL ITEMS
INTERIOR ARCHITECTURE OF OFFICES
SIGNAGE
CUSTOM ARTWORK FOR OFFICES
MARA HOE ESTRIBOU BONDBOOK / MARKETING MATERIALS, ADVERTISING, STATIONERY, FORMS SYSTEM
MARA HOE ESTRIBOU LORD, ABBETT & CO. / IDENTITY
SCOPE OF WORK:
LOGO DESIGN AND BRAND IDENTIFICATION GUIDELINES
BRAND MESSAGING
TRAINING AND SUPERVISION OF “IN-HOUSE” DESIGN AND MARKETINGTEAMS ON NEW BRAND GUIDELINES
PRODUCT MARKETING LITERATURE KITSAND CAPABILITIES BROCHURES
FAMILY OF FUNDS LITERATURE SYSTEMS:QUARTERLY FUND FACT BOOKS, FUND FACT SHEETS, ANNUAL REPORTS,AND PROSPECTUS
NEWSLETTERS AND TEMPLATES
REGIONAL ADVERTISING
EXTENSIVE PRODUCT COLOR CODING SYSTEM
ELECTRONIC GRID, STYLE, CHART/TABLEAND ARTWORK LIBRARIES
MULTIPLE STATIONERY SYSTEMS(BOTH PRINTED AND ELECTRONIC)
EXTENSIVE STATEMENT SYSTEM(CONTENT AND PAPER STOCKS)
PRESENTATION MATERIALS
SIGNAGE
BANNERS / POSTERS
PROMOTIONAL ITEMS
CORPORATE WEB SITE
PROPRIETARY “INTELLIGENCE” WEB SITE
MULTIPLE POWERPOINTTEMPLATE SYSTEMS
BROADCAST AND PROJECTION BACKDROPS
SCREEN SAVERS AND DESKTOP PATTERNS
MARA HOE ESTRIBOU LORD, ABBETT & CO. / CAPABILITIES BROCHURE, PRODUCT MARKETING LITERATURE, NEWSLETTER
MARA HOE ESTRIBOU LORD, ABBETT & CO. / FAMILY OF FUNDS LITERATURE SYSTEMS
MARA HOE ESTRIBOU NEARCOM / LOGO
MARA HOE ESTRIBOU SEXTANT SEARCH PARTNERS / STATIONERY AND ANNOUNCEMENT CARD
MARA HOE ESTRIBOU AGFA / PROMOTIONAL BROCHURE
MARA HOE ESTRIBOU FISH & NEAVE / RECRUITING BROCHURE
NOVANTRONE®is aregistered trademark of Serono, Inc. ©2006Serono,Inc. xx-xxxxx 04/06All rightsreserved. Printed in the USA
when itcomes toworsening ms,timingiseverything.when it comes to worsening ms,timing is everything.
w h e n i t c o m e s t o w o r s e n i n g m s , t i m i n g i s e v e r y t h i n g .
a continuing dialogue on current treatment options and the role of NOVANTRONE® in the treatment of worsening MS.
TM:talkingMS
FRONTCOVER
BAC
KCO
VER
INSI
DE
BAC
KCO
VER
POC
KET
Thank you for your continued interest in NOVANTRONE.Included in this folder are:• Important screening and monitoring recommendations for NOVANTRONE• A complimentary NOVANTRONE pen • A Rx pad holder to use when prescribing NOVANTRONE
We hope you find the enclosed materials useful in your practice.
Write NOVANTRONE Write “Dispense as Written”
Please see enclosed full Prescribing Information for Novantrone. Reference: 1. NOVANTRONE Full Prescribing Information. Serono, Inc.
IN THE TREATMENT OFWORSENING MS…
TIMING AND SAFETY: THE CORNERSTONES OF NOVANTRONE®TREATMENT
Timing is everythingProven benefits in patients with when
used as EDSS score between 3.0 and 6.0
with stepwise progressive disability.
Safety considerationsManageable side effects
recommended in the PI.
MARA HOE ESTRIBOU SERONO / NOVANTRONE / PROMOTIONAL K IT I I
NOVANTRONE® is a registered trademark of Serono, Inc. ©2006 Serono, Inc. xx-xxxxx 04/06 All rights reserved. Printed in the USA
w h e n i t c o m e s t o w o r s e n i n g m s , t i m i n g i s e v e r y t h i n g . w h e n i t c o m e s t o w o r s e n i n g m s , t i m i n g i s e v e r y t h i n g .
when it comes to worsening ms,timing is everything.
acontinuing dialogue on current treatment optionsand the role of NOVANTRONE®
inthe treatment of worsening MS.
TM
:talkingMS
FRONT COVER
BAC
KCO
VER
INSID
EBA
CK
COVER PO
CKET
Thank youfor your continued interest in NOVANTRONE.Included in this folder are:•Important screening and monitoring recommendations for NOVANTRONE•A complimentary NOVANTRONE pen •A Rx pad holder to use when prescribing NOVANTRONE
We hope you find the enclosed materials useful in your practice.
Write NOVANTRONE Write “Dispense as Written”
Please see enclosed full Prescribing Information for Novantrone.Reference: 1. NOVANTRONE Full Prescribing Information. Serono, Inc.
IN THE TREATMENT OF WORSENING MS…
TIMING AND SAFETY: THE CORNERSTONES OF NOVANTRONE® TREATMENT
Timing is everythingProven benefits in patients with when
used as EDSS score between 3.0 and 6.0
with stepwise progressive disability.
Safety considerationsManageable side effects
recommended in the PI.
A D V A N C E S I N
M S M A N A G E M E N TBAYER HEALTHCARE PHARMACEUTICALS INC.NATIONAL CONSULTANTS MEETING
Saturday
Breakfast ..................................................Commonwealth Room B..........................................7:00 AM – 8:00 AM
General Session Commonwealth Rooms C&D 8:00 AM – 10:15 AM
Chairman’s Welcome.........................................................................................................................8:00 AM – 8:15 AM
Lecture 1: The Changing Paradigm in MS Treatment......................................................................8:15 AM – 8:45 AM
Lecture 2: New Considerations for Early MS Intervention..............................................................8:45 AM – 9:30 AM
Break ..............................................................................................................................................9:30 AM – 9:45 AM
Lecture 3: Advances in Multiple Sclerosis Research: MRI............................................................................................................................9:45 AM – 10:15 AM
Panel Discussion Q&A.................................................................................................................10:15 AM – 10:45 AM
Travel to Workshop Sessions.................................................................................................10:45 AM – 11:00 AM
Workshop Sessions 11:00 AM – 12:00 PM
The Clinical Implication of NAbs................Congress Room AQuality of Life in MS:
Managing Patient Concerns......Congress Room B
Lunch ......................................................Commonwealth Room B ..........................................12:00 PM – 1:00 PM
Workshop Sessions 1:00 PM – 2:00 PM
Quality of Life in MS: Managing Patient Concerns......Congress Room A
The Clinical Implication of NAbs................Congress Room B
Keynote Address Howe Room 6:30 PM – 7:00 PM
The Benefits and Risks of Future MS Therapies
Dinner ......................................................Howe Room ....................................................................................7:00 PM
Sunday
Breakfast ................................................Commonwealth Room B ..........................................7:00 AM – 8:00 AM
General Session Commonwealth Rooms C&D 8:00 AM – 9:30 AM
Bayer Clinical Commitment (with Q&A) ........................................................................................8:00 AM – 8:30 AM
Faculty Case Studies with Audience Response ..............................................................................8:30 AM – 9:30 AM
Break..........................................................................................................................................9:30 AM – 9:45 AM
General Session Commonwealth Rooms C&D 9:45 AM – 11:00 AM
Participant Case Studies with Audience Response ........................................................................9:45 AM – 10:45 AM
Closing Remarks............................................................................................................................10:45 AM – 11:00 AM
Departures................................................................................................................................................11:00 AM
MARA HOE ESTRIBOU BAYER HEATHCARE / BETASERON
Managing Patient Concerns......Congress Room AThe Clinical Implication of NAbs................Congress Room B
Howe Room 6:30 The Benefits and Risks of Future MS Therapies
......................................................Howe Room
................................................Commonwealth Room B
General Session Commonwealth Rooms C&D 8:00
Bayer Clinical Commitment (with Q&A) ........................................................................................8:00 Faculty Case Studies with Audience Response ..............................................................................8:30
..........................................................................................................................................
General Session Commonwealth Rooms C&D 9:45
Participant Case Studies with Audience Response ....................................................................................................................................................................................................10:45
................................................................................................................................................
Managing Patient Concerns......Congress Room AThe Clinical Implication of NAbs................Congress Room B
The Benefits and Risks of Future MS Therapies
......................................................
................................................
General Session Commonwealth Rooms C&D 8:00
Bayer Clinical Commitment (with Q&A)Faculty Case Studies with Audience Response
..........................................................................................................................................
General Session Commonwealth Rooms C&D 9:45
Participant Case Studies with Audience Response ....................................................................................................................................................................................................10:45
................................................................................................................................................
T H E K E Y A C C O U N T S P E C I A L I S T
13
A L O G I S T I C S G U I D E F O R
12
New Advisory Board Request (Therapeutics) Invitation Letter
13
M S M M O D E R A T O R ’ S G U I D E
Slide 15: Immediate Betaseron Treatment vs DelayedBetaseron Treatment Resulted in a 1 Year Delay inConversion From CIS to CDMS
Read Title
• Is this information significant enough forpatients to know?
Slide 16: Immediate Betaseron Treatment vs DelayedBetaseron Treatment Reduces Risk of CDMS in AllPredefined Subgroups
As you can see, regardless of the subgroup, immediate Betaseron treatment had a significanteffect on delaying conversion to CDMS.
• Of the patients that come to you with CIS, which of these subgroups is the most common presentation?
• As a result of this data or your own personalexperience do you believe Betaseron is the bestchoice for initial treatment for these patients?
Slide 17: Immediate Betaseron Treatment vs DelayedBetaseron Treatment Reduces the Risk of SustainedDisability Progression by 40% at 3 years
The most compelling result of the BENEFIT study appears to be the disability data. Patients who started on Betaseron after the first event experience less disability at 3 years compared to those who delayed treatment until after the second event or at the 2 year point.
In this study, let the audience know that ittook 6 months to confirm disability endpoints.
No other DMT has demonstrated this. In theCHAMPS Follow-Up Study there was no effect on disability.
• What are your thoughts on this information?
• Do you think the disability data will causehealthcare professionals to treat CIS moreaggressively?
• As a result of this information do you expect to start Betaseron earlier in the course of the disease?
10
Slide 18: Does BENEFIT Address Barriers to first-lineBetaseron Treatment?
• Has the BENEFIT study adequately addressed thefirst and second barriers to treatment?
Let’s review the summary before moving on…
Slide 19: BENEFIT Results Summary
• How do you think this information will changeyour first-line prescribing habits?
• As a result of this information, do you thinkBetaseron should be the drug of choice fornewly diagnosed patients?
• What information from this trial do you plan to share with your patients?
Slide 20: Does BENEFIT Address Barriers to first-lineBetaseron Treatment?
Next we would like to seek your input on how the BENEFIT results might help us to addressthe last barrier: concern that the patient will not accept treatment regimen.
Let’s take a look at the safety and tolerabilityresults.
Slide 21: Safety and Tolerability of Betaseron
Walk the group through the slide: make note of the fact that the population from the BENEFIT trial differs from the RRMS population in the pivotal study, which is represented in the prescribing information.
11
M S M M O D E R A T O R ’ S G U I D EM S M
Slide 15: Immediate Betaseron Treatment vs DelayedBetaseron Treatment Resulted in a 1 Year Delay inConversion From CIS to CDMS
Read Title
• Is this information significant enough forpatients to know?
Slide 16: Immediate Betaseron Treatment vs DelayedBetaseron TrTrT eatment Reduces Risk of CDMS in AllPredefined Subgroups
As you can see, regardless of the subgroup, immediate Betaseron treatment had a significanteffect on delaying conversion to CDMS.
EARLY TREATMENT OF MSREGIONAL ADVISORY BOARD MEETINGS
A Moderator’s Guide for the MSM
T H E K E Y A C C O U N T S P E C I A L I S T
13
A L O G I S T I C S G U I D E F O R
12
New Advisory Board Request (Therapeutics) Invitation Letter
13
experience do you believe Betaseron is the bestchoice for initial treatment for these patients?
A L O G I S T I C S
EARLY TREATMENT
OF MULTIPLE SCLEROSIS
REGIONAL ADVISORY BOARD MEETINGS
A Logistics Guide for the Key Account Specialist
EARLY TREATMENT OF MSREGIONAL ADVISORY BOARD MEETINGS
MARA HOE ESTRIBOU EMD SERONO / SEROSTIM / MARKETING MATERIALS, AD CAMPAIGN
E v e n i n t h e H A A R T y e a r s , H I V - a s s o c i a t e d w a s t i n g r e m a i n s a c o n c e r n
50% increase in 6-month risk of ≥ 5% weight-loss in later HAART years than early HAART years*1
• Even a 5% unintended weight-loss in 6 months markedly increases the risk of death.
I n a d d i t i o n t o w e i g h t - l o s s , p a t i e n t s w i t h H I V - a s s o c i a t e d w a s t i n g c a n a l s o e x p e r i e n c e 2
• Low energy
• Weakness
• Fatigue
• Inability or difficulty in doing normal daily activities such as cleaning or walking
*Among majority of patients not trying to lose weight
0 0.2 0.4 0.6 0.8 1 1.2 1.4 1.6
p<.01
N=713
Later HAART years(1998-2003)
Early HAART years(1995-1997)
Risk of 5% or greater weight-loss in 6 months
S e r o s t i m ® o f f e r s a p o i n t o f d i f f e r e n t i a t i o n i n t h e t r e a t m e n t o f H I V - a s s o c i a t e d w a s t i n g
Only Serostim®‚ has been clinically proven to significantly improve physical endurance and health-related quality of life (HRQoL) outcomes
• In addition to increasing weight and lean body mass (LBM) in patients with HIV-associated wasting3-4
Please see accompanying full Prescribing Information provided in pocket.
There’s more to HIV-associated wasting than weight lossS e r o s t i m ®‚ [somatropin (rDNA origin) for injection]f o r y o u r p a t i e n t s w i t h H I V - a s s o c i a t e d w a s t i n g
Serostim® [somatropin (rDNA origin) for injection] has been proven to help build leanbody mass — putting on much needed pounds.
Unlike other therapies for wasting, Serostim® has also been proven to increase physicalendurance — which may help you work, play and live more like you used to.
Serostim®. So you can start getting on with what you’ve been missing.
Visit www.serostim.com to learn more. And ask your doctor if Serostim® can help you.
Important Safety Information: Serostim® [somatropin (rDNA origin) for injection] is indicated for the treatment of HIV wasting in patientsreceiving antiretroviral therapy. Serostim® should not be used in patients with active cancer or in patients hospitalized in intensive care. Patientswith a history of diabetes or related glucose intolerance problems should be monitored closely during Serostim® treatment. Common side effects with Serostim® include joint pain and swelling. These side effects can usually be managed with treatment or a change in Serostim® dose.For more information refer to the Brief Summary of Important Information on the other side of this ad. Serostim®
is available by prescription only. Serostim® is a registered trademark of Serono, Inc. ©2006 Serono, Inc. XX-XXXX 12/06 All rights reserved. For more information call 800-714-2437.
FDA APPROVED FOR HIV-ASSOCIATED WASTING. . .
Life is too good for wasting
MARA HOE ESTRIBOU ASTORIA FEDERAL SAVINGS / BRAND CAMPAIGN
MARA HOE ESTRIBOU ASTORIA FEDERAL SAVINGS / BRAND CAMPAIGN
MARA HOE ESTRIBOU AMERICAN MUSEUM OF NATURAL HISTORY / EARLY AND EXTINCT RELATIVES OF MAMMALS EXHIBIT
Related Documents
